Zopapogene imadenovec clinical trials
How each study uses zopapogene imadenovec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zopapogene imadenovec studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Aug 2025 · PAPZIMEOS · BLA 125832 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PRGN-2012
- 1
Studies by the year they started
4 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Precigen, Inc (3) · National Cancer Institute (NCI) (1)
Studies
Open first, then newest update. How each study uses zopapogene imadenovec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT07756840Written as PRGN-2012
- Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in ChildrenNot yet recruitingPhase 3Precigen, IncNCT07901738Written as Zopapogene imadenovec-drba
- Zopa Retreatment and Vector Shedding in Adults With RRPRecruitingPhase 4Precigen, IncNCT06538480Written as Zopapogene imadenovec (Zopa)
- Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory PapillomatosisActive, not recruitingPhase 1/2Precigen, IncNCT04724980Written as PRGN-2012 - Phase I; Dose Level 1
Codes
What other systems call zopapogene imadenovec · ClinicalTrials.gg INT002193
- MeSH (NLM) C000732019zopapogene imadenovecOne source NLM
- UNII (FDA) C525BYS7TPZOPAPOGENE IMADENOVECConfirmed FDA, NLM
- NCI Thesaurus C207022Zopapogene ImadenovecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732019 | zopapogene imadenovec | One source NLM |
| UNII (FDA) | C525BYS7TP | ZOPAPOGENE IMADENOVEC | Confirmed FDA, NLM |
| NCI Thesaurus | C207022 | Zopapogene Imadenovec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.